Potential role of Drug Repositioning Strategy (DRS) for management of tauopathy
Third Author's Department
Institute of Global Health & Human Ecology
Tauopathy is a term that has been used to represent a pathological condition in which hyperphosphorylated tau protein aggregates in neurons and glia which results in neurodegeneration, synapse loss and dysfunction and cognitive impairments. Recently, drug repositioning strategy (DRS) becomes a promising field and an alternative approach to advancing new treatments from actually developed and FDA approved drugs for an indication other than the indication it was originally intended for. This paradigm provides an advantage because the safety of the candidate compound has already been established, which abolishes the need for further preclinical safety testing and thus substantially reduces the time and cost involved in progressing of clinical trials. In the present review, we focused on correlation between tauopathy and common diseases as type 2 diabetes mellitus and the global virus COVID-19 and how tau pathology can aggravate development of these diseases in addition to how these diseases can be a risk factor for development of tauopathy. Moreover, correlation between COVID-19 and type 2 diabetes mellitus was also discussed. Therefore, repositioning of a drug in the daily clinical practice of patients to manage or prevent two or more diseases at the same time with lower side effects and drug-drug interactions is a promising idea. This review concluded the results of pre-clinical and clinical studies applied on antidiabetics, COVID-19 medications, antihypertensives, antidepressants and cholesterol lowering drugs for possible drug repositioning for management of tauopathy.
Zaki, M. O.
Elsherbiny, D. A.
Azab, S. S.
(2022). Potential role of Drug Repositioning Strategy (DRS) for management of tauopathy. Life sciences, 291, 120267–120267.
Zaki, Mennatallah, et al.
"Potential role of Drug Repositioning Strategy (DRS) for management of tauopathy." Life sciences, vol. 291, 2022, pp. 120267–120267.